Compare EML & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EML | ENGN |
|---|---|---|
| Founded | 1858 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Industrial Machinery/Components | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.5M | 117.2M |
| IPO Year | 1995 | N/A |
| Metric | EML | ENGN |
|---|---|---|
| Price | $25.05 | $1.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $21.08 |
| AVG Volume (30 Days) | 10.9K | ★ 725.3K |
| Earning Date | 05-12-2026 | 06-11-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | ★ 185.40 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $248,970,345.00 | N/A |
| Revenue This Year | $19.05 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $228.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $1.40 |
| 52 Week High | $29.91 | $12.25 |
| Indicator | EML | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 43.75 |
| Support Level | $24.84 | $1.68 |
| Resistance Level | $27.19 | $1.85 |
| Average True Range (ATR) | 0.80 | 0.09 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 71.06 | 35.39 |
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to the industrial market. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It has one reportable segment: Engineered Solutions, which provides engineered solutions mainly for the commercial transportation and logistics markets. This segment offers a diverse product line of custom and standard vehicular and industrial hardware, including turnkey returnable packaging solutions, blow molds, compression latches, draw latches, hinges, camlocksaccess, mirrors, and mirror-cameras, among other products. Geographically, the group derives maximum revenue from the United States.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.